Economy 1 MIN READ

BRIEF-Shanghai Henlius Biotech Announces License Agreement With Getz Pharma For Rights Of Handayuan

February 23, 2022By Reuters

Shanghai Henlius Biotech Inc 2696.HK:

  • ANNOUNCES LICENSE AGREEMENT WITH GETZ PHARMA FOR RIGHTS OF HANDAYUAN

  • TO GRANT LICENSE TO GETZ PHARMA TO COMMERCIALISE ADALIMUMAB INJECTION IN PAKISTAN, PHILIPPINES, AMONG OTHER COUNTRIES

Further company coverage: 2696.HK

((Reuters.Briefs@thomsonreuters.com;))

This article originally appeared on reuters.com

Read More Articles About: